Natera

Austin, Texas, U.S. All United States companies → — Founded 2004

Point-of-Care Diagnostics Specialty-Focused AI

Maternal-Fetal Medicine Obstetrics & Gynecology Oncology

Lab & Diagnostics OB/GYN AI Oncology AI

Public — $152M

Website Claim this company

Products

Natera Genetic Testing

Natera

Lab & Diagnostics

Natera is a global leader in cell-free DNA testing, offering AI-driven genetic testing and analysis in oncology, women's health, organ health, and rare diseases. Physicians can order tests and receive comprehensive reports for diagnostic and treatment planning, leveraging Natera's clinically validated and regulatory-compliant solutions.

Natera offers various pricing options including insurance coverage, prompt-pay cash prices, and financial assistance programs. they are in-network with most national and regional healthcare plans, including medicare. patients can receive pre-test cost estimates.

See all 1 product →

About Natera

Natera is a leading diagnostics company specializing in non-invasive, cell-free DNA (cfDNA) testing across critical medical fields: oncology, women’s health, and organ health. The company leverages proprietary molecular biology techniques, advanced bioinformatics software, and artificial intelligence (AI) to detect single molecules in blood samples, enabling highly accurate and comprehensive genetic insights. Their mission is to integrate personalized genetic testing and diagnostics into standard clinical care, facilitating earlier and more targeted interventions for improved patient outcomes.

In oncology, Natera offers the Signatera™ molecular residual disease (MRD) test, which is tumor-informed and used for early detection of cancer recurrence and monitoring treatment response, often months before traditional imaging. For women’s health, their portfolio includes the Panorama™ non-invasive prenatal test (NIPT) for chromosomal abnormalities and microdeletions, Horizon™ for advanced carrier screening, Empower™ for hereditary cancer screening, Vistara™ for single-gene prenatal screening, and Anora™ for miscarriage testing. In organ health, Natera provides the Prospera™ transplant assessment test to detect organ injury early and inform treatment strategies, and the Renasight™ kidney gene panel.

Natera’s technology is supported by extensive clinical validation, with hundreds of peer-reviewed publications and participation in large prospective studies. The company is actively advancing its AI capabilities, including a collaboration with NVIDIA to develop multimodal AI foundation models, aiming to enhance diagnostic accuracy, deepen biological understanding, and support personalized treatment decisions across its focus areas.

Focus Areas

Oncology Women's Health Organ Health Cell-free DNA testing Genetic testing Molecular diagnostics Precision medicine

Business Intelligence

Key Investors	Jpmorgan Chase & Co, Vanguard Group Inc, Price T Rowe Associates Inc /md/, BlackRock, Inc., Wellington Management Group Llp, Farallon Capital Management Llc, State Street Corp, Coatue Management Llc, Geode Capital Management, Llc, Aqr Capital Management Llc
Partnerships	NVIDIA (for AI foundation model development)
Acquisitions	Foresight Diagnostics (December 2025), Invitae's reproductive health assets (January 2024)
Technology	Proprietary cell-free DNA (cfDNA) technology platform, novel molecular biology techniques, bioinformatics software, Constellation cloud-based platform, AI foundation models

What Physicians Need to Know

Oncology

Natera specializes in personalized, tumor-informed molecular residual disease (MRD) assessment and recurrence monitoring with Signaterau2122. This test is designed to detect circulating tumor DNA (ctDNA) earlier than traditional methods, aiding in treatment response monitoring and identifying recurrence. They also offer comprehensive genomic profiling (Altera) to identify clinically relevant DNA & RNA biomarkers and hereditary cancer testing (Empower) for genes associated with over 12 cancer types. Natera's oncology platform leverages AI for virtual genomic profiling and immunotherapy response prediction.

Women's Health

Natera provides a comprehensive suite of genetic tests for women's health, including Panoramau2122 for non-invasive prenatal testing (NIPT) which screens for chromosomal abnormalities and is known for its high accuracy. Horizonu2122 offers advanced carrier screening for over 500 hereditary diseases. Other offerings include Empoweru2122 for hereditary cancer risk, Vistarau2122 for single-gene NIPT, Anorau2122 for miscarriage testing, and Fetal RhD NIPT.

Organ Health

Natera's Organ Health solutions focus on detecting organ injury and assessing transplant rejection. Prosperau2122 is a donor-derived cell-free DNA (dd-cfDNA) test that provides early warning signs of transplant rejection for kidney, heart, and lung, often months before clinical symptoms. Renasightu2122 is a genetic test to determine if there is a genetic cause for kidney disease or increased risk due to family history, analyzing 385 genes associated with chronic kidney disease.

Cell-free DNA Testing & Molecular Diagnostics

Natera is a global leader and pioneer in cell-free DNA (cfDNA) testing, utilizing a proprietary technology platform that combines novel molecular biology techniques with advanced bioinformatics software. Their approach precisely detects and differentiates cfDNA from fetal, tumor, or donor organ cells using a simple blood draw. The technology focuses on targeted Single Nucleotide Polymorphisms (SNPs) for high accuracy and sensitivity, even down to a single molecule of DNA.

Genetic Testing & Precision Medicine

Natera is committed to making personalized genetic testing and diagnostics part of the standard of care. They leverage their extensive experience in molecular technology and proprietary artificial intelligence to support personalized medical care, offering actionable insights for treatment decisions and risk stratification across oncology, women's health, and organ health. Their tests are backed by over 400 peer-reviewed publications and participation in large prospective studies.

Physician Tip

For physicians, Natera stands out due to its highly accurate, non-invasive cell-free DNA tests that provide actionable insights for personalized patient management. The ability to detect disease earlier, such as cancer recurrence with Signatera or transplant rejection with Prospera, can significantly impact treatment strategies and patient outcomes. Natera's commitment to extensive clinical validation (over 400 peer-reviewed publications) ensures scientific rigor and reliability. The company also offers comprehensive support, including complimentary genetic counseling sessions and a focus on making testing affordable for patients. Furthermore, Natera's ongoing investment in AI and multimodal modeling promises even more refined risk assessment and treatment optimization in the future.

Natera offers seamless electronic medical record (EMR) integration with all major systems, including being a founding member of the Epic Aurau2122 network. This two-way integration allows test results to flow directly into patient EMRs, streamlining workflows, reducing administrative burden, and ensuring timely access to actionable insights for physicians. They also integrate with platforms like Flatiron Health's OncoEMRu00ae for oncology, providing a unified ordering experience and electronic results delivery.

At a glance

Founded 2004

HQ Austin, Texas, U.S. · United States

Team size 6,140

CEO Steve Chapman

Funding Public — $152M

Products 1

Visit site

Products by Natera

1 product in the directory

Natera Genetic Testing

Natera

Lab & Diagnostics

What the Web Says

Natera is a genetic testing company with a mixed reputation. While their product, particularly the Panorama NIPT test, is often praised for its accuracy and comprehensiveness by healthcare providers and patients, the company's internal operations and customer service receive significant criticism. Employees frequently report issues with management, workload, and compensation, leading to a generally negative employer sentiment.

Overall: Mixed

Strengths

Accurate and comprehensive genetic testing products (e.g., Panorama NIPT)
Tests provide valuable information for patients and clinicians
Advanced technology in genetic screening
Positive impact on early detection of genetic conditions
Some users report good customer support for specific product inquiries
Contribution to medical advancements in prenatal and cancer screening

Limitations

Poor management and leadership, according to employee reviews
High workload and burnout reported by employees
Inadequate compensation and benefits for some roles
Frequent complaints about customer service and billing issues from patients/providers
Lack of work-life balance for employees
Internal communication issues and disorganization

Based on reviews from: Glassdoor, Reddit, G2, Capterra, Healthcare IT News (general sentiment)

Last updated: 2026-07-22

Videos

News, demos, and interviews about Natera.

Loading videos...

Videos load interactively. If none appear, search YouTube for Natera →

View all on YouTube

Press & Coverage

Natera, Inc.

Signaterau2122 MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study

A study published in JAMA Dermatology found Natera's Signatera test to be a significantly stronger and earlier predictor of recurrence in Merkel cell carcinoma compared to the traditional AMERK test. Signatera demonstrated 90% sensitivity in predicting recurrences, outperforming AMERK's 55%.

2026-07

Natera, Inc.

Finalized MolDx LCD Includes Expanded Coverage for Natera's Prosperau2122 Portfolio

Natera announced that a finalized MolDx Local Coverage Determination (LCD) now includes expanded coverage for its Prosperau2122 portfolio, which offers molecular testing for solid organ allograft rejection. This strengthens coverage for Prospera in transplant monitoring.

2026-07

Natera, Inc.

Natera Announces IVDR Certification for Signaterau2122 Across Multiple Cancers

Natera's Signatera test has received certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR) for use across multiple cancer types. This certification is a significant regulatory milestone for the company.

2026-07

Natera, Inc.

Signaterau2122 Receives Regulatory Approval in Japan for Colorectal Cancer

Natera announced that its Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for patients with colorectal cancer in the adjuvant setting. This marks the first PMDA-approved molecular residual disease test in Japan.

2026-06

Natera, Inc.

NCCN Recommends ctDNA-MRD Testing Using Signaterau2122 Technology in Landmark Bladder Cancer Guideline Update

The National Comprehensive Cancer Network (NCCN) has updated its guidelines to recommend ctDNA-MRD testing using Natera's Signatera technology for muscle-invasive bladder cancer. This inclusion follows positive clinical trial data.

2026-06

Natera, Inc.

Natera to Launch Enhanced Panoramau2122 NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology

Natera is launching an enhanced Panorama non-invasive prenatal test (NIPT) utilizing novel SNP-informed deep sequencing technology. This advancement aims to improve performance at low fetal fraction levels and reduce the no-call rate to 0.5%.

2026-05

Natera, Inc.

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology

Natera announced a landmark oncology data program for the 2026 ASCO Annual Meeting, featuring 35 abstracts across molecular residual disease (MRD) testing and other innovations. The presentations will highlight Natera's Treatment on MRD (TOMR) approach and the broad utility of Signatera.

2026-05

Natera, Inc.

Natera Announces Commercial Launch of Zenithu2122 Genomics for Rare Disease Diagnosis

Natera has commercially launched Zenith genomics, a next-generation whole genome sequencing assay designed to improve the detection of rare diseases. This platform was developed by MyOme, with whom Natera has an exclusive partnership.

2026-03

Frequently Asked Questions

What are Natera's primary oncology products, and how do they utilize cell-free DNA for precision cancer management?

Natera's key oncology products include Signatera, a tumor-informed molecular residual disease (MRD) test that uses circulating tumor DNA (ctDNA) to detect recurrence earlier and monitor treatment response. Latitude is a tissue-free MRD test for colorectal cancer, while Altera provides comprehensive genomic profiling to identify relevant biomarkers and guide treatment options. These tests aim to optimize therapy decisions from diagnosis through survivorship by providing actionable insights.

In Women's Health, what genetic testing services does Natera offer, and what are their applications for prenatal and reproductive health?

Natera offers a comprehensive suite of genetic tests for women's health, including Panorama for non-invasive prenatal testing (NIPT) to screen for chromosomal abnormalities, and Horizon for advanced carrier screening to assess genetic risks for couples planning a family. Other offerings include Empower for hereditary cancer testing, Vistara for single-gene NIPT, Anora for miscarriage testing, and Fetal Focus for inherited conditions when paternal testing is unavailable. These services support informed decision-making across family planning, pregnancy, and understanding pregnancy loss.

How does Natera's Prospera test leverage cell-free DNA technology for organ transplant assessment, and what are its clinical advantages?

Natera's Prospera test utilizes donor-derived cell-free DNA (dd-cfDNA) technology to non-invasively assess the risk of rejection in kidney, heart, and lung transplant patients. It offers early warning signs of transplant rejection, with studies showing improved diagnostic accuracy and better clinical decision-making compared to traditional biomarkers. This allows providers to develop timely treatment plans to protect the transplanted organ and potentially reduce the need for surveillance biopsies.

What measures does Natera take to ensure the regulatory compliance and analytical validity of its molecular diagnostic tests?

Natera operates ISO 13485-certified and CAP-accredited laboratories, which are also certified under the Clinical Laboratory Improvement Amendments (CLIA), ensuring high standards for its molecular diagnostic tests. The company emphasizes scientific rigor and integrity, with its tests supported by over 400 peer-reviewed publications demonstrating their analytical and clinical validity. Natera is committed to meeting or exceeding applicable industry and regulatory standards for all its offerings.

Can you explain Natera's approach to test pricing, insurance coverage, and the support resources available for healthcare providers?

Natera welcomes all insurance plans and is an in-network provider with many national and regional healthcare plans, which can help reduce patient out-of-pocket costs. They offer financial assistance programs, prompt-pay cash prices, and interest-free payment plans to ensure affordability. Natera also provides support to healthcare providers through a staff of medical professionals who can assist with test interpretation and patient counseling, along with dedicated billing support.

What is Natera's current market position, and what strategic partnerships or initiatives contribute to its long-term stability and growth?

Natera is recognized as a global leader in cell-free DNA testing, with a strong market presence in women's health, oncology, and organ health. The company maintains a significant market share in non-invasive prenatal testing and holds an early-mover advantage in the growing molecular residual disease (MRD) testing market. Natera's long-term stability and growth are driven by substantial R&D investments, continuous product diversification, and strategic partnerships aimed at expanding market access and strengthening clinical evidence.